Latest News and Press Releases
Want to stay updated on the latest news?
-
ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF): Share option programmeAccording to the guidelines for incentive payments adopted at the Company's annual general meeting on 12 March 2018, the Board of...
-
ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) Articles of Association most recently amended by the shareholders at the AGM held on 12 March 2018 ...
-
ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) Vedtægter vedtaget på den ordinære generalforsamling i ALK den 12. marts 2018 ALK Vedtægter_12032018_final ...
-
Copenhagen, 2018-03-12 17:22 CET (GLOBE NEWSWIRE) -- ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) held its annual general meeting on 12 March 2018. The annual general meeting...
-
København, 2018-03-12 17:22 CET (GLOBE NEWSWIRE) -- (c) ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) afholdt ordinær generalforsamling den 12. marts 2018. På generalforsamlingen skete...
-
Copenhagen, 2018-03-02 16:49 CET (GLOBE NEWSWIRE) -- ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF): In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market...
-
København, 2018-03-02 16:49 CET (GLOBE NEWSWIRE) -- ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF): I henhold til artikel 19 i EU forordning nr. 596/2014 af 16. april 2014 om markedsmisbrug...
-
Copenhagen, 2018-02-21 10:00 CET (GLOBE NEWSWIRE) -- Allergy immunotherapy company ALK today announced that its sublingual allergy immunotherapy (SLIT) tablet ACARIZAX® is now available on...
-
Copenhagen, 2018-02-21 10:00 CET (GLOBE NEWSWIRE) -- Allergy immunotherapy company ALK today announced that its sublingual allergy immunotherapy (SLIT) tablet ACARIZAX® is now available on...
-
København, 2018-02-16 07:00 CET (GLOBE NEWSWIRE) -- ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) meddelte i dag, at selskabets partner i Japan, Torii, har modtaget godkendelse fra de japanske...